Company Encyclopedia
View More
name
SHANGHAI YIZHONG
688091.SH
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.
3.159 T
688091.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking105/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.58%C
    • Profit Margin9.30%B
    • Gross Margin84.68%A
  • Growth ScoreD
    • Revenue YoY-1.44%D
    • Net Profit YoY-64.99%D
    • Total Assets YoY3.74%C
    • Net Assets YoY1.65%C
  • Cash ScoreC
    • Cash Flow Margin1075.82%B
    • OCF YoY-1.44%D
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreA
    • Gearing Ratio5.36%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    OFILM Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    OFILM Group Co., Ltd. reported its earnings for the nine months ending September 30, 2025. The company achieved sales of CNY 15,815.88 million, up from CNY 14,471.55 million the previous year. However, it incurred a net loss of CNY 68.05 million, a decline from a net income of CNY 47.12 million in the prior year. Basic and diluted loss per share from continuing operations were CNY 0.0207, compared to earnings per share of CNY 0.0144 and CNY 0.0143, respectively, a year ago.

    marketscreener·
    SZ
    002456
    +0.36%
    marketscreener·
    SZ
    002456
    +0.36%

    HuaYuan Securities: The potential of PD1/VEGF/IL-2 is promising, insisting on innovative drugs as the main line for the whole year

    Huayuan Securities released a research report indicating that the pharmaceutical industry will continue to improve marginally in 2025, with operational performance expected to further improve in 2026. It is recommended to focus on structurally high-growth sub-sectors and individual stocks, particularly the integration of the PD1/VEGF/IL-2 triple antibody mechanism. It is recommended to pay attention to SHANGHAI YIZHONG, as its developed triple antibody YXC-001 has high feasibility in treatment strategies and is expected to show significant advantages in efficacy and immune activation

    Zhitong·
    SH
    688091
    -1.87%
    Zhitong·
    SH
    688091
    -1.87%

    Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

    Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    002262
    +0.57%
    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    002262
    +0.57%

    SHANGHAI YIZHONG plans to repurchase shares for 30 million to 35 million yuan

    According to the Zhitong Finance APP, SHANGHAI YIZHONG announced that the company plans to repurchase shares for between 30 million and 35 million yuan, with the repurchase price not exceeding 106.08 yuan per share, and all will be used to maintain the company's value and shareholder rights

    Zhitong·
    SH
    688091
    -1.87%
    Zhitong·
    SH
    688091
    -1.87%

    Shanghai Yizhong Pharmaceutical Chairman Proposes Up to 35-Million-Yuan Share Buyback

    (MT Newswires) -- Shanghai Yizhong Pharmaceutical (SHA:688091) Chairman Zhou Jinsong proposed to repurchase between 30 million yuan and 35 million yuan of shares, according to a Friday filing with the Shanghai bourse. The shares will be repurchased within 12 months from the announcement of the buyback results and shareholding changes, the filing said. Shares closed 3% higher during afternoon trading on Friday.

    marketscreener·
    SH
    688091
    -1.87%
    marketscreener·
    SH
    688091
    -1.87%
    © 2025 Longbridge｜Disclaimer